All In Biotech

Drug Trial Radar · NCT04616040

A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer

A Non-interventional Registration Study Evaluating the Usage of Camrelizumab in the Treatment of Unresectable Locally Advanced/Recurrent or Metastatic Chinese Patients With Esophageal Cancer

Last checked: Nov 20, 2026Latest source record: Nov 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

1,030

Planned (sponsor's estimate)

Start

Dec 1, 2020

Primary completion

Dec 1, 2023

Study completion Dec 1, 2026

Sponsor

Lead sponsor
Peking UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 4, 2020

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial is a multi-center, open, observational registration study, which aims to evaluate the safety and efficacy of Camrelizumab (anti-PD-1 antibody) in the treatment of Chinese patients with advanced esophageal cancer in the real world.

Conditions

  • Esophageal Cancer

Interventions

  • CamrelizumabDrug

    The recommended formulation of Camrelizumab is 200 mg every time, or 3 mg/Kg according to body weight, intravenously infused.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events of CamrelizumabTime frame: an expected average of 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.